Targeting topoisomerase II activity in NSCLC with 9-aminoacridine derivatives

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Etoposide and other type-II human topoisomerase (TOPOII) poisons are widely used for the treatment of many different cancer types, including nonsmall cell lung cancer (NSCLC). However, there is a risk for the development of therapy-related secondary leukemia following treatment with these TOPOII poisons. Five to seven years is the typical latency period for the development of secondary leukemia. One of the strategies to overcome this issue is to develop agents that do not act as poisons but still effectively inhibit topoisomerase activity. This has led to the development of acridine-based agents, which are catalytic TOPOII inhibitors, that do not generate DNA strand breaks that can lead to secondary malignancies in in vitro tests. Materials and Methods: In this study, we showd antiproliferative activity of a series of acridine-based catalytic inhibitors of TOPOII using four NSCLC cell lines (H460, A549, H2009 and H2030). Cells were treated with four acridine-based compounds for 72 h. Results: The results indicate that these compounds inhibit NSCLC cell proliferation with half-maximal effective concentration (EC50) ranging from 8.15 to 42.09 μM. Combination therapy with cisplatin resulted in increased potency. Poly (ADP-ribose) polymerase cleavage and Guava Nexin assays confirm that the primary mode of cell death was by apoptosis. Conclusion: This current work is part of a series of studies for this panel of acridine-based compounds bearing TOPOII-inhibitory activity against different solid tumor types. The acridine-based agents were found to substantially reduce NSCLC cell viability and induce apoptosis. In addition, the acridine-based compounds sensitized cells to cisplatin as measured by cell viability. The results are consistent with prior work on mesothelioma, small-cell lung cancer and pancreatic cancer with this same panel of 9-aminoacridine derivatives. These findings support further development of this type of catalytic TOPOII inhibitor as a novel agent for NSCLC therapy.

Original languageEnglish (US)
Pages (from-to)5211-5218
Number of pages8
JournalAnticancer Research
Volume35
Issue number10
StatePublished - Jan 1 2015

Fingerprint

Aminacrine
Acridines
Type II DNA Topoisomerase
Non-Small Cell Lung Carcinoma
Poisons
Cisplatin
Cell Survival
Leukemia
Psidium
Apoptosis
Neoplasms
DNA Breaks
Poly(ADP-ribose) Polymerases
Mesothelioma
Small Cell Lung Carcinoma
Etoposide
Pancreatic Neoplasms
Cell Death
Therapeutics
Cell Proliferation

Keywords

  • 9-aminoacridine derivatives
  • Human topoisomerase II
  • Non-small cell lung cancer

Cite this

Targeting topoisomerase II activity in NSCLC with 9-aminoacridine derivatives. / Ferguson, David M; Jacobson, Blake A; Jay-Dixon, Joe; Patel, Manish R; Kratzke, Robert A; Raza, Ahmad.

In: Anticancer Research, Vol. 35, No. 10, 01.01.2015, p. 5211-5218.

Research output: Contribution to journalArticle

@article{f547b5a7a456413fad995ebd24b35764,
title = "Targeting topoisomerase II activity in NSCLC with 9-aminoacridine derivatives",
abstract = "Background: Etoposide and other type-II human topoisomerase (TOPOII) poisons are widely used for the treatment of many different cancer types, including nonsmall cell lung cancer (NSCLC). However, there is a risk for the development of therapy-related secondary leukemia following treatment with these TOPOII poisons. Five to seven years is the typical latency period for the development of secondary leukemia. One of the strategies to overcome this issue is to develop agents that do not act as poisons but still effectively inhibit topoisomerase activity. This has led to the development of acridine-based agents, which are catalytic TOPOII inhibitors, that do not generate DNA strand breaks that can lead to secondary malignancies in in vitro tests. Materials and Methods: In this study, we showd antiproliferative activity of a series of acridine-based catalytic inhibitors of TOPOII using four NSCLC cell lines (H460, A549, H2009 and H2030). Cells were treated with four acridine-based compounds for 72 h. Results: The results indicate that these compounds inhibit NSCLC cell proliferation with half-maximal effective concentration (EC50) ranging from 8.15 to 42.09 μM. Combination therapy with cisplatin resulted in increased potency. Poly (ADP-ribose) polymerase cleavage and Guava Nexin assays confirm that the primary mode of cell death was by apoptosis. Conclusion: This current work is part of a series of studies for this panel of acridine-based compounds bearing TOPOII-inhibitory activity against different solid tumor types. The acridine-based agents were found to substantially reduce NSCLC cell viability and induce apoptosis. In addition, the acridine-based compounds sensitized cells to cisplatin as measured by cell viability. The results are consistent with prior work on mesothelioma, small-cell lung cancer and pancreatic cancer with this same panel of 9-aminoacridine derivatives. These findings support further development of this type of catalytic TOPOII inhibitor as a novel agent for NSCLC therapy.",
keywords = "9-aminoacridine derivatives, Human topoisomerase II, Non-small cell lung cancer",
author = "Ferguson, {David M} and Jacobson, {Blake A} and Joe Jay-Dixon and Patel, {Manish R} and Kratzke, {Robert A} and Ahmad Raza",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "35",
pages = "5211--5218",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Targeting topoisomerase II activity in NSCLC with 9-aminoacridine derivatives

AU - Ferguson, David M

AU - Jacobson, Blake A

AU - Jay-Dixon, Joe

AU - Patel, Manish R

AU - Kratzke, Robert A

AU - Raza, Ahmad

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Etoposide and other type-II human topoisomerase (TOPOII) poisons are widely used for the treatment of many different cancer types, including nonsmall cell lung cancer (NSCLC). However, there is a risk for the development of therapy-related secondary leukemia following treatment with these TOPOII poisons. Five to seven years is the typical latency period for the development of secondary leukemia. One of the strategies to overcome this issue is to develop agents that do not act as poisons but still effectively inhibit topoisomerase activity. This has led to the development of acridine-based agents, which are catalytic TOPOII inhibitors, that do not generate DNA strand breaks that can lead to secondary malignancies in in vitro tests. Materials and Methods: In this study, we showd antiproliferative activity of a series of acridine-based catalytic inhibitors of TOPOII using four NSCLC cell lines (H460, A549, H2009 and H2030). Cells were treated with four acridine-based compounds for 72 h. Results: The results indicate that these compounds inhibit NSCLC cell proliferation with half-maximal effective concentration (EC50) ranging from 8.15 to 42.09 μM. Combination therapy with cisplatin resulted in increased potency. Poly (ADP-ribose) polymerase cleavage and Guava Nexin assays confirm that the primary mode of cell death was by apoptosis. Conclusion: This current work is part of a series of studies for this panel of acridine-based compounds bearing TOPOII-inhibitory activity against different solid tumor types. The acridine-based agents were found to substantially reduce NSCLC cell viability and induce apoptosis. In addition, the acridine-based compounds sensitized cells to cisplatin as measured by cell viability. The results are consistent with prior work on mesothelioma, small-cell lung cancer and pancreatic cancer with this same panel of 9-aminoacridine derivatives. These findings support further development of this type of catalytic TOPOII inhibitor as a novel agent for NSCLC therapy.

AB - Background: Etoposide and other type-II human topoisomerase (TOPOII) poisons are widely used for the treatment of many different cancer types, including nonsmall cell lung cancer (NSCLC). However, there is a risk for the development of therapy-related secondary leukemia following treatment with these TOPOII poisons. Five to seven years is the typical latency period for the development of secondary leukemia. One of the strategies to overcome this issue is to develop agents that do not act as poisons but still effectively inhibit topoisomerase activity. This has led to the development of acridine-based agents, which are catalytic TOPOII inhibitors, that do not generate DNA strand breaks that can lead to secondary malignancies in in vitro tests. Materials and Methods: In this study, we showd antiproliferative activity of a series of acridine-based catalytic inhibitors of TOPOII using four NSCLC cell lines (H460, A549, H2009 and H2030). Cells were treated with four acridine-based compounds for 72 h. Results: The results indicate that these compounds inhibit NSCLC cell proliferation with half-maximal effective concentration (EC50) ranging from 8.15 to 42.09 μM. Combination therapy with cisplatin resulted in increased potency. Poly (ADP-ribose) polymerase cleavage and Guava Nexin assays confirm that the primary mode of cell death was by apoptosis. Conclusion: This current work is part of a series of studies for this panel of acridine-based compounds bearing TOPOII-inhibitory activity against different solid tumor types. The acridine-based agents were found to substantially reduce NSCLC cell viability and induce apoptosis. In addition, the acridine-based compounds sensitized cells to cisplatin as measured by cell viability. The results are consistent with prior work on mesothelioma, small-cell lung cancer and pancreatic cancer with this same panel of 9-aminoacridine derivatives. These findings support further development of this type of catalytic TOPOII inhibitor as a novel agent for NSCLC therapy.

KW - 9-aminoacridine derivatives

KW - Human topoisomerase II

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84942770905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942770905&partnerID=8YFLogxK

M3 - Article

C2 - 26408679

AN - SCOPUS:84942770905

VL - 35

SP - 5211

EP - 5218

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -